Type 2 diabetes mellitus: what is the optimal treatment regimen?
- 8 March 2004
- journal article
- review article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 116 (5), 23-29
- https://doi.org/10.1016/j.amjmed.2003.10.017
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- A futile metabolic cycle activated in adipocytes by antidiabetic agentsNature Medicine, 2002
- Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.Circulation, 2002
- Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 DiabetesDiabetes Care, 2002
- Nonhypoglycemic Effects of ThiazolidinedionesAnnals of Internal Medicine, 2001
- Association between C-reactive protein and features of the metabolic syndrome: a population-based study.Diabetes Care, 2000
- Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonistsJCI Insight, 2000
- Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle CellsCirculation, 2000
- Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.Diabetes Care, 1999
- Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.JCI Insight, 1998
- NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome XDiabetologia, 1997